Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24‐week, open‐label, controlled trial (
            STOP‐OB
            )

Toru Kitazawa; Hiroaki Seino; Hiroshi Ohashi; Takeshi Inazawa; Masahiro Inoue; Masumi Ai; Midori Fujishiro; Hisamoto Kuroda; Masayo Yamada; Motonobu Anai; Hisamitsu Ishihara

doi:10.1111/dom.14059

Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24‐week, open‐label, controlled trial ( STOP‐OB )

Diabetes Obesity and Metabolism ◽

10.1111/dom.14059 ◽

2020 ◽

Vol 22 (9) ◽

pp. 1659-1663 ◽

Cited By ~ 1

Author(s):

Toru Kitazawa ◽

Hiroaki Seino ◽

Hiroshi Ohashi ◽

Takeshi Inazawa ◽

Masahiro Inoue ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Dipeptidyl Peptidase ◽

Oral Agent ◽

Open Label ◽

Dipeptidyl Peptidase 4 ◽

The Third ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-i

Diabetes Obesity and Metabolism ◽

10.1111/dom.12264 ◽

2014 ◽

Vol 16 (8) ◽

pp. 761-765 ◽

Cited By ~ 12

Author(s):

K. Kobayashi ◽

H. Yokoh ◽

Y. Sato ◽

M. Takemoto ◽

D. Uchida ◽

...

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Open Label ◽

Dipeptidyl Peptidase 4 ◽

Glucosidase Inhibitor ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes

Diabetes Obesity and Metabolism ◽

10.1111/dom.12988 ◽

2017 ◽

Vol 19 (11) ◽

pp. 1602-1609 ◽

Cited By ~ 7

Author(s):

Ira Gantz ◽

Taro Okamoto ◽

Yuka Ito ◽

Kotoba Okuyama ◽

Edward A. O'Neill ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Dipeptidyl Peptidase ◽

Safety And Efficacy ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Review for "Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus DPP ‐4 inhibitor in Japanese type 2 diabetes patients: a randomized, 24‐week, open label, controlled trial ( STOP‐OB )"

10.1111/dom.14059/v2/review2 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Oral Agent ◽

Open Label ◽

The Third ◽

Diabetes Patients

Download Full-text

Decision letter for "Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus DPP ‐4 inhibitor in Japanese type 2 diabetes patients: a randomized, 24‐week, open label, controlled trial ( STOP‐OB )"

10.1111/dom.14059/v2/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Oral Agent ◽

Open Label ◽

The Third ◽

Diabetes Patients

Download Full-text

Comparative Efficiency of Sulfonylurea and/or Dipeptidyl Peptidase-4 inhibitor in Basal-Supported Oral Therapy in Japanese Patients with Type 2 Diabetes (JDDM39)

Journal of Diabetes and Obesity ◽

10.15436/2376-0949.15.030 ◽

2015 ◽

Vol 2 (3) ◽

pp. 1-6

Author(s):

Keiko Arai ◽

Keyword(s):

Type 2 Diabetes ◽

Oral Therapy ◽

Japanese Patients ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Comparative Efficiency ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Basal Supported Oral Therapy

Download Full-text

Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial

PLoS ONE ◽

10.1371/journal.pone.0228004 ◽

2020 ◽

Vol 15 (1) ◽

pp. e0228004 ◽

Cited By ~ 2

Author(s):

Takeshi Onoue ◽

Motomitsu Goto ◽

Eri Wada ◽

Mariko Furukawa ◽

Takayuki Okuji ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Apolipoprotein B ◽

Controlled Trial ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2011.08.016 ◽

2012 ◽

Vol 95 (2) ◽

pp. e27-e28 ◽

Cited By ~ 41

Author(s):

Takashi Nomiyama ◽

Yuko Akehi ◽

Hiromasa Takenoshita ◽

Ryoko Nagaishi ◽

Yuichi Terawaki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Dipeptidyl Peptidase ◽

Contributing Factors ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Dipeptidyl peptidase-4 inhibitor improves glycemic variability in multiple daily insulin-treated type 2 diabetes: a prospective randomized-controlled trial

Diabetology International ◽

10.1007/s13340-021-00513-6 ◽

2021 ◽

Author(s):

Fukumi Yoshikawa ◽

Hiroshi Uchino ◽

Tomoko Nagashima ◽

Shuki Usui ◽

Masahiko Miyagi ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Controlled Trial ◽

Glycemic Variability ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Prospective Randomized Controlled Trial

Download Full-text

Author response for "Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus DPP ‐4 inhibitor in Japanese type 2 diabetes patients: a randomized, 24‐week, open label, controlled trial ( STOP‐OB )"

10.1111/dom.14059/v3/response1 ◽

2020 ◽

Author(s):

Toru Kitazawa ◽

Hiroaki Seino ◽

Hiroshi Ohashi ◽

Takeshi Inazawa ◽

Masahiro Inoue ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Author Response ◽

Oral Agent ◽

Open Label ◽

The Third ◽

Diabetes Patients

Download Full-text

Review for "Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus DPP ‐4 inhibitor in Japanese type 2 diabetes patients: a randomized, 24‐week, open label, controlled trial ( STOP‐OB )"

10.1111/dom.14059/v2/review1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Oral Agent ◽

Open Label ◽

The Third ◽

Diabetes Patients

Download Full-text